Engflag

Sefro

Quick links to important sections

Sefro

Sefro_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sefro

What is Sefro? (Cephradine)

Property Description
Active Ingredient Cephradine (Cefradine)
Pharmaceutical Forms Capsules, Suspension, Powder for Injection
Pharmacological Class First-Generation Cephalosporin Antibiotic
General Purpose Anti-infective agent for bacterial elimination
Origin Semi-synthetic

Sefro: Identity and Pharmacological Classification

Sefro is a medicine whose active ingredient is Cephradine, a compound also referenced as Cefradine. This medicinal product is classified as a first-generation cephalosporin antibiotic, placing it within the larger beta-lactam family of anti-infective agents. Cephradine is a semi-synthetic compound, meaning its structure is chemically derived from a natural substance but modified to optimize its therapeutic properties. It functions as a single-ingredient product, containing only Cephradine as the source of its antibacterial effect.

Understanding Cephradine's Mechanism and General Purpose

The general purpose of this medicine is to provide an effective, broad-spectrum method for clearing bacterial presence in the body. Cephradine achieves this through a powerful bactericidal mechanism by directly attacking the structural integrity of the bacterial cell. The compound specifically interferes with the final, essential stage of cell wall synthesis, which is critical for the bacterium's survival, ensuring the definitive elimination of susceptible bacteria. First-generation cephalosporins, like Cephradine, are effective against common Gram-positive bacteria and certain Gram-negative organisms. This clinically recognized action confirms the drug's role in clearing infections caused by a wide range of common bacterial types.

Available Preparations of Sefro

Sefro is manufactured in several primary dosage forms to accommodate various patient needs and routes of delivery. The availability of oral preparations, specifically solid capsules and a liquid suspension, is a key feature that simplifies treatment for different patient groups. Additionally, Cephradine is available as a specialized powder for injection, which requires reconstitution for parenteral administration in clinical settings. This duality of available forms, offering both convenient oral use and direct systemic administration, ensures broad applicability in medical treatment protocols.

Regulatory References

  1. U.S. Food and Drug Administration
  2. broad-spectrum

What side effects are possible with Sefro?

Amoxicillin: Possible side effects and safety information

This section outlines the adverse reactions and safety information for Amoxicillin as documented in official government regulatory sources.

Safety Restrictions and Contraindications

Amoxicillin is contraindicated (should not be used) in patients with a history of severe hypersensitivity (e.g., anaphylaxis, Stevens-Johnson Syndrome) to Amoxicillin or any other penicillin antibiotic. A warning exists for potential cross-allergenicity with cephalosporins. The drug is also restricted in patients with infectious mononucleosis, as a high incidence of non-allergic rash is documented in this population.

Common and Expected Adverse Reactions

The most frequently observed adverse reactions, reported as Common in clinical data, typically involve the digestive system and skin:

  • Gastrointestinal: Diarrhea, Nausea, Vomiting.
  • Skin: Non-severe Rash (e.g., maculopapular rash).

Serious and Clinically Significant Adverse Reactions

While rare, certain adverse reactions documented in regulatory sources are considered serious and require immediate attention:

  • Severe Hypersensitivity: Including Anaphylaxis (a sudden, life-threatening reaction) and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • Gastrointestinal: Clostridium difficile–Associated Diarrhea (CDAD), which may occur during or several weeks after treatment.
  • Systemic Effects: Potential for liver injury (e.g., cholestatic jaundice) and kidney issues (Crystalluria, Interstitial Nephritis). These effects may require monitoring, particularly in patients with pre-existing kidney impairment, where dose adjustment is often required.

Contextual Safety Notes

The safety profile is structured by regulatory bodies to distinguish between common, expected side effects and rare, life-threatening events. The presence of these documented risks defines the limits and precautions for the medicine's use, without providing individual clinical advice.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding Sefro (Cephradine) overdose is based strictly on descriptions and actions mandated by government regulatory documents.

Feature Regulatory Statement
Documented overdose presentations The symptoms of Cephradine overdose are documented as non-specific, generally including nausea, vomiting, diarrhoea, and gastric upsets (Source 1.6).
Physiological systems affected Potential for neuromuscular hypersensitivity and seizures (convulsions), primarily affecting the central nervous system (CNS) at high systemic levels (Source 1.2, 2.3).
Population-specific overdose notes Increased risk of complications (seizures) is specifically noted in patients with impaired renal function due to elevated systemic drug concentrations (Source 2.3).
Emergency-response statements The patient must be treated symptomatically and supportive measures should be instituted as required. Gastric lavage may be necessary if a large amount is ingested (Source 1.5, 1.6).
When immediate medical help is required Seek immediate medical attention at the first sign of any adverse drug reaction, including overdose (Source 1.5, 1.6).

Official Overdose Statements

  • No specific antidote is mentioned in the official prescribing information; treatment is limited to supportive care.
  • Procedural steps documented for managing high systemic levels include the ability to remove the drug by hemodialysis or peritoneal dialysis (Source 1.2, 2.3).

Connection to the Overall Overdose Profile

The regulatory guidance defines the overdose profile by listing non-specific gastrointestinal symptoms as expected manifestations, immediately pivoting to the necessary emergency action: seeking immediate medical attention. Management is strictly symptomatic and supportive, noting that procedural interventions like dialysis can be used for drug clearance. Crucially, the label highlights the specific, severe risk of seizures in patients with impaired renal function, a population-specific warning that requires urgent consideration.

Therapeutic Uses of Sefro

What Sefro Treats: Main Uses and Benefits

Sefro (Cephradine) is commonly used to help manage acute symptoms in conditions presenting with systemic or localized discomfort. First-generation agents like Sefro are applied across several key therapeutic areas where additional symptomatic support is needed.

Indications and Symptom Management

This medication is generally used to help manage symptom clusters that may become intense or disruptive in conditions such as pharyngitis, tonsillitis, otitis media, and bronchopneumonia. Its application is relevant for treating susceptible infections in the respiratory tract, the urinary system (including cystitis and pyelonephritis), and in the skin and soft tissues (such as cellulitis and abscesses). The medication may be part of symptomatic management when symptoms interfere with functional stability.

The therapeutic goal is to address symptoms related to systemic imbalance like fever and chills, alongside localized discomfort. In cases of chronic recurrent infections, it is often applied during acute episodes when symptoms become more noticeable.

Quick Fact: Supports management of Fever and Pain

The use of Sefro contributes to improved comfort during periods of heightened symptoms. This provides supportive relief and helps the patient cope more steadily with symptom fluctuations associated with acute infection.

Regulatory References

  1. NIH Bookshelf

Eligibility and Restrictions for Use

Who Can and Cannot Use Sefro? (Cephradine)

This section outlines the official eligibility and non-eligibility rules for Sefro as mandated by government regulatory authorities.

Absolute Restrictions

Sefro is absolutely contraindicated in patients who have a known history of hypersensitivity or severe allergic reaction to Cephradine or to any other antibiotic in the cephalosporin class.

Conditional Eligibility and Cautions

Population/Condition Eligibility Status (Regulatory)
Impaired Renal Function Conditional use; requires caution and mandatory dosage reduction based on creatinine clearance levels.
History of Penicillin Allergy Use must be with great caution due to the risk of cross-allergenicity between penicillins and cephalosporins.
Infants under 9 Months Use is not established; safety and effectiveness have not been confirmed by regulatory bodies for this age group.
Older Adults Use is permitted, but caution is advised due to the higher likelihood of reduced renal function, which may require monitoring.
Pregnancy Classified as Category B; use is advised only when clearly established as essential by a healthcare provider.

This framework ensures that use remains within the officially defined parameters for patient safety and suitability, as documented in prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Sefro (Cephradine) defines interactions primarily in terms of systemic exposure modification and risks of additive toxicity.

Substance / Category Official Interaction Statement
Probenecid Documented to increase and prolong Sefro’s serum concentrations by competitively inhibiting its renal tubular secretion.
Loop Diuretics (e.g., Furosemide) Co-administration is associated with an increased potential for nephrotoxicity (additive kidney toxicity risk).
Aminoglycoside Antibiotics May enhance the nephrotoxicity associated with the use of these antibiotics.
Oral Products containing Zinc These supplements may interfere with the gastrointestinal absorption of Sefro, potentially reducing its overall effectiveness.

Interaction-Related Constraints

Specific products containing the mineral Zinc, such as certain multivitamins, must be separated from Sefro. Official documentation recommends that these oral products be administered at least 3 hours after the dose of Sefro to mitigate the absorption interference.

Population-Specific Notes

As a cephalosporin, Sefro may be associated with a fall in prothrombin activity. This risk is noted as a specific consideration for patients already receiving Anticoagulation Therapy or those with underlying renal or liver dysfunction.

Mechanism of Action

How Sefro Works

Sefro (Cephradine) is an antimicrobial agent whose mechanism initiates at the molecular level by targeting bacterial Penicillin-Binding Proteins ( PBPs), enzymes essential for cell wall construction. The drug's structure facilitates its binding to the PBP active site and induces irreversible inhibition through a covalent bond, thereby inactivating the enzyme.

This inhibition leads to a specific blockade of the final cross-linking step in the bacterial peptidoglycan synthesis pathway. The resulting formation of a structurally unstable and fragile cell wall compromises the bacterium's ability to maintain its osmotic stability.

The loss of structural integrity causes the bacterial cell to lyse (rupture) rapidly due to internal pressure. This molecular cascade results in a bactericidal effect, which is the destruction of susceptible bacterial cells. The drug's activity is biologically constrained by mechanisms of resistance, such as the production of beta-Lactamase enzymes that chemically hydrolyze the drug, or the presence of altered PBPs that prevent effective binding.

Dosage and Administration Information

How Sefro (Cephradine) is Used: Official Administration Guidelines

This section details the formal administration and dosing procedures for Sefro. These instructions provide the standard framework for proper use.

Administration Routes and Dosing Schedule

Sefro is approved for oral administration (capsules or suspension) and parenteral administration (intramuscular (IM) injection or intravenous (IV) injection/infusion). Parenteral use is primarily reserved for patients unable to tolerate oral medication or for severe infections.

Feature Official Dosing Rule
Standard Adult Oral Dose 250 mg to 1 g, typically every 6 hours (q6h) or every 12 hours (q12h).
Maximum Adult Dose Up to 1 g every 6 hours (4 g/day) orally, or up to 8 g daily parenterally for severe cases.
Pediatric Dose 25 to 100 mg/ kg/ day in divided doses, not to exceed the adult maximum of 4 g/ day.

Procedural and Population-Specific Instructions

Sefro may be administered without regard to meals as absorption is rapid. The timing of administration is fixed at multiple intervals daily to maintain therapeutic concentrations.

  • Preparation: The powder for suspension must be reconstituted with water and shaken prior to use. IV injections must be administered slowly over 3 to 5 minutes.
  • Duration of Course: Treatment must be continued for a minimum of 48 to 72 hours after the patient becomes asymptomatic. For infections caused by beta-haemolytic streptococci, a minimum 10-day course is required to prevent late complications.
  • Renal Impairment: Dose reduction is mandatory for patients with reduced kidney function. The dosing schedule must be modified based on the patient's Creatinine Clearance (CrCl) to prevent drug accumulation. For example, the dose is lowered to 250 mg every 6 hours for CrCl 5 to 20 mL/ min.
  • Step-Down Therapy: Patients may be safely transitioned from the injectable form to the oral form at the same dosage level once clinically appropriate.

Recent Clinical Evidence

Research Evidence Overview of Studies for Sefro

This overview describes the types of research that have explored Sefro (Cephradine) and what the studies monitored, helping to put its available evidence into context. Research provides context but not individual predictions, and studies help show what has been observed so far in specific groups.

Evidence for Use in Respiratory Tract Infections

Sefro was studied for its use in conditions involving the respiratory tract, such as infections of the throat, tonsils, and lungs. The research primarily consists of clinical studies and trials exploring short-term symptom changes. Researchers examined outcomes related to physical discomfort and systemic imbalance, such as the patient-reported experience of fever or pain. Studies also monitored whether the specific causative bacteria were eradicated from the infection site.

The studies reported on patterns observed regarding measured changes in acute, disruptive episodes. Research describes patterns measured during the study period, often related to the time observed for the bacterial pathogen to be eradicated. What remains uncertain is the drug's performance against newer antibiotics, as comparative evidence is lacking in modern, large-scale trials. Furthermore, follow-up durations were limited in many studies, meaning long-term effects are not fully established or characterized for this type of infection.

Evidence for Use in Urinary Tract Infections

Research has explored Sefro's use in urinary tract infections (UTIs), including both short-term, acute cases and chronic recurrent conditions. This area features specific Randomized Comparative Trials (RCTs). These studies monitored the eradication of the bacteria from the urinary tract and measured changes in patient-reported outcomes describing perceived discomfort. Some RCTs explored outcomes when comparing shorter (e.g., 5-day) and longer (e.g., 10-day) treatment durations.

Data show patterns related to the rate of bacterial eradication observed in the studied populations. However, the results apply only to the populations studied. The evidence is more focused on uncomplicated UTIs, and data for certain groups remain insufficient regarding very severe or complicated kidney infections (pyelonephritis) or cases associated with functional limitations.

Key Studies & References

  1. Cephalosporins: A Comprehensive Review (Monograph)
  2. Clinical Trials and Systematic Reviews on First-Generation Cephalosporin Efficacy in Uncomplicated Urinary Tract Infections (Evidence Summary)

Frequently Asked Questions (FAQ)

Common questions about Sefro (FAQ)

Q: What is the main function of Sefro?

Sefro is an orally administered medication that functions as a non-steroidal anti-inflammatory drug, commonly known as an NSAID. According to official product information, its primary role is to reduce inflammation and help relieve various types of pain.

Q: Is Sefro an over-the-counter medicine?

Regulatory documents state that Sefro is classified as a prescription-only medicine. This means it is only available with a valid prescription from a licensed healthcare provider.

Q: How quickly does Sefro start working to relieve pain?

Studies and official information indicate that Sefro generally begins to provide noticeable pain relief about 30 minutes to 1 hour after a patient takes a dose. The medication typically reaches its highest concentration in the bloodstream approximately 1 to 2 hours after being administered.

Q: What are the common uses of Sefro?

According to the official product information, Sefro is indicated for the treatment of pain and inflammation. Indications for Sefro include the management of symptoms associated with various conditions, such as rheumatoid arthritis, osteoarthritis, and other acute pain states.

Q: Does Sefro need to be taken with food?

Regulatory documents state that Sefro may be taken either with or without food. Regulatory labeling notes that taking the medication with food may be an option, and patients sometimes find this reduces potential stomach irritation.

Q: Is Sefro addictive?

Official information indicates that Sefro is not classified as a narcotic pain reliever. As a non-steroidal anti-inflammatory drug (NSAID), it does not carry a known risk for physical dependence or addiction.

How should Sefro be stored and disposed of?

How to Store and Dispose of Sefro

Storage of Sefro (Cephradine) must adhere strictly to regulatory conditions to ensure stability. Unreconstituted forms, such as capsules and powder, must be stored at Controlled Room Temperature, not exceeding 30 C, and protected from light and moisture. The product must also be stored out of the sight and reach of children.

Stability After Reconstitution

Form Post-Reconstitution Storage Temperature Maximum Stability Time
Oral Suspension Refrigerated (2 C to 8 C) 14 days

Disposal Requirements

Disposal of unused or expired medicine should utilize an authorized drug take-back program. If a program is unavailable, the product may be mixed with an undesirable substance (e.g., used coffee grounds) and sealed in a container for household trash. The medicine must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBangladesh

Equivalent of Sefro found in:

A-Z Index: